201552-68-3

Upstream product

• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 167853-87-4 N-(5-(4-cyanobenzyloxy)-2-(bromoacetyl)aminobenzoyl)-β-alanine ethyl ester 
• 151979-08-7 N-(5-(4-cyanobenzyloxy)-2-nitrobenzoyl)-β-alanine ethyl ester 
• 151979-09-8 N-(5-(4-cyanobenzyloxy)-2-aminobenzoyl)-β-alanine ethyl ester 
• 151979-06-5 α-(3-formyl-4-nitrophenoxy)-p-tolunitrile 
• 17201-43-3 4-cyanobenzyl bromide 
• 4244-84-2 ethyl β-alaninate hydrochloride 
• 151979-07-6 α-(3-carboxy-4-nitrophenoxy)-p-tolunitrile 

Downstream Products

• 167853-99-8 7-[[4-cyanophenyl]methoxy]-3,4-dihydro-1H-1,4-benzodiazepine-2-thione-5-one-4-propanoic acid ethyl ester 
• 167854-05-9 8-[(4-cyanophenyl)methoxy]-6-oxo-4H-[1,2,3,4]tetrazolo[4,5-a][1,4]benzodiazepine-5(6H)-propanoic acid ethyl ester 
• 167854-04-8 8-[[4-(iminoaminomethyl)phenyl]methoxy]-7,13-dihydro-5,13-dioxo-quinazolino[3,2-a][1,4]benzodiazepine-6(5H)-propanoic acid ethyl ester 
• 167854-03-7 8-[[4-cyanophenyl]methoxy]-7,13-dihydro-5,13-dioxo-quinazolino[3,2-a][1,4]benzodiazepine-6(5H)-propanoic acid ethyl ester 
• 167854-01-5 8-[[4-cyanophenyl]methoxy]-1-methyl-6-oxo-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-5(6H)-propanoic acid ethyl ester 
• 167854-00-4 8-[[4-cyanophenyl]methoxy]-1-methyl-6-oxo-4H-imidazo[1,2-a][1,4]benzodiazepine-5(6H)-propanoic acid ethyl ester 
• 167854-21-9 7-[[4-cyanophenyl]methoxy]-2-methylmercaptyl-3,4-dihydro-1,4-benzodiazepine-5-one-4-propanoic acid ethyl ester 
• 151979-05-4 1-methyl-4-(2-carboxyethyl)-7-(4-cyanobenzyloxy)-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione ethyl ester 

Relevant academic research and scientific papers

Tricyclic inhibitors of the GPIIb IIIa receptor

A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPIIb IIIa receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

Tricyclic inhibitors of the vitronectin receptor

A tricylic benzodiazepine derivative that acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPIIb IIIa receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.

Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists

Antagonists of the glycoprotein GPIIb/IIIa are a promising class of antithrombotic agents offering potential advantages over present antiplatelet agents (i.e., aspirin and ticlopidine). Novel tricyclic nonpeptidal GPIIb/IIIa antagonists have been prepared and evaluated in vitro as antagonists of fibrinogen binding to the purified GPIIb/IIIa receptor and as inhibitors of platelet aggregation. The work presented demonstrates the robustness of the benzodiazepinedione (BZDD) scaffold, which can be functionalized at the N1-C2 amide as well as at C7, to provide structural diversity and allow optimization of the physiochemical and pharmacological properties of the BZDD based GPIIb/IIIa antagonists. In addition, the resulting new class of tricyclic GPIIb/IIIa antagonists could be used to probe for additional binding interactions on the GPIIb/IIIa receptor and perhaps lead to BZDD based GPIIb/IIIa antagonists with increased potency. The tricyclic molecules reported herein demonstrate that a heterocyclic ring can be fused to the benzodiazepinedione scaffold with retention of anti-aggregatory potency and in the case of tetrazole 30i, increased potency relative to the bicyclic analogue 1c. Copyright (C) 1998 Elsevier Science Ltd.

Tricyclic inhibitors of the GPIIb IIIa receptor

A trycylic benzodiazepine derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPIIb IIIa receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.